Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Ocugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy

Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).

Leia mais: Ocugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy
Grafa
Health

NRx Pharmaceuticals reports strategic debt elimination and pivot to clinical revenue in 2025

NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.

Leia mais: NRx Pharmaceuticals reports strategic debt elimination and pivot to clinical revenue in 2025
Grafa
Health

Achieve Life Sciences sets 2026 PDUFA date for Cytisinicline following NDA acceptance

Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.

Leia mais: Achieve Life Sciences sets 2026 PDUFA date for Cytisinicline following NDA acceptance
Grafa
Health

Karyopharm reports mixed Phase 3 SENTRY results in frontline myelofibrosis

Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.

Leia mais: Karyopharm reports mixed Phase 3 SENTRY results in frontline myelofibrosis